AGP Executive Report
Last update: 4 hours agoVaccine & Pharma Finance: Valneva reported €64.0M in first-half 2026 product sales, kept full-year guidance at €135–150M, and said it has a strong €121.5M cash position after a reserved offering; the company also flagged a restructuring program with expected positive impacts later this year and said regulatory decisions for its Lyme disease vaccine candidate are due within the next 12 months. Urban Health & Climate: A new look at tropical cities warns that urban heat islands can worsen hot-humid health risks, especially for vulnerable residents, and points to practical fixes like shade, green roofs/walls, lighter surfaces, and better street airflow—though many cities can’t afford full implementation as El Niño strengthens. Public Health & Policy: Mauritius’ drug crisis is back in the spotlight after the arrest of a minister’s husband and related questions about political responsibility and safeguards, with an editorial urging a broader, rule-of-law approach that doesn’t let one scandal crowd out the bigger strategy.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
